BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 16107692)

  • 1. Role of Stat3 in regulating p53 expression and function.
    Niu G; Wright KL; Ma Y; Wright GM; Huang M; Irby R; Briggs J; Karras J; Cress WD; Pardoll D; Jove R; Chen J; Yu H
    Mol Cell Biol; 2005 Sep; 25(17):7432-40. PubMed ID: 16107692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis.
    Niu G; Wright KL; Huang M; Song L; Haura E; Turkson J; Zhang S; Wang T; Sinibaldi D; Coppola D; Heller R; Ellis LM; Karras J; Bromberg J; Pardoll D; Jove R; Yu H
    Oncogene; 2002 Mar; 21(13):2000-8. PubMed ID: 11960372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo.
    Gao L; Zhang L; Hu J; Li F; Shao Y; Zhao D; Kalvakolanu DV; Kopecko DJ; Zhao X; Xu DQ
    Clin Cancer Res; 2005 Sep; 11(17):6333-41. PubMed ID: 16144938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of signal transducer and activator of transcription 3 activities by p53 tumor suppressor in breast cancer cells.
    Lin J; Jin X; Rothman K; Lin HJ; Tang H; Burke W
    Cancer Res; 2002 Jan; 62(2):376-80. PubMed ID: 11809683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Ras homologue member I directly inhibits signal transducers and activators of transcription 3 translocation and activity in human breast and ovarian cancer cells.
    Nishimoto A; Yu Y; Lu Z; Mao X; Ren Z; Watowich SS; Mills GB; Liao WS; Chen X; Bast RC; Luo RZ
    Cancer Res; 2005 Aug; 65(15):6701-10. PubMed ID: 16061651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated signal transducers and activators of transcription 3 signaling induces CD46 expression and protects human cancer cells from complement-dependent cytotoxicity.
    Buettner R; Huang M; Gritsko T; Karras J; Enkemann S; Mesa T; Nam S; Yu H; Jove R
    Mol Cancer Res; 2007 Aug; 5(8):823-32. PubMed ID: 17699108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells.
    Mora LB; Buettner R; Seigne J; Diaz J; Ahmad N; Garcia R; Bowman T; Falcone R; Fairclough R; Cantor A; Muro-Cacho C; Livingston S; Karras J; Pow-Sang J; Jove R
    Cancer Res; 2002 Nov; 62(22):6659-66. PubMed ID: 12438264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting STAT3 affects melanoma on multiple fronts.
    Kortylewski M; Jove R; Yu H
    Cancer Metastasis Rev; 2005 Jun; 24(2):315-27. PubMed ID: 15986140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy.
    Xi S; Gooding WE; Grandis JR
    Oncogene; 2005 Feb; 24(6):970-9. PubMed ID: 15592503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. G-quartet oligonucleotides: a new class of signal transducer and activator of transcription 3 inhibitors that suppresses growth of prostate and breast tumors through induction of apoptosis.
    Jing N; Li Y; Xiong W; Sha W; Jing L; Tweardy DJ
    Cancer Res; 2004 Sep; 64(18):6603-9. PubMed ID: 15374974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. STAT proteins: novel molecular targets for cancer drug discovery.
    Turkson J; Jove R
    Oncogene; 2000 Dec; 19(56):6613-26. PubMed ID: 11426647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential recognition of response elements determines target gene specificity for p53 and p63.
    Osada M; Park HL; Nagakawa Y; Yamashita K; Fomenkov A; Kim MS; Wu G; Nomoto S; Trink B; Sidransky D
    Mol Cell Biol; 2005 Jul; 25(14):6077-89. PubMed ID: 15988020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells.
    Kanda N; Seno H; Konda Y; Marusawa H; Kanai M; Nakajima T; Kawashima T; Nanakin A; Sawabu T; Uenoyama Y; Sekikawa A; Kawada M; Suzuki K; Kayahara T; Fukui H; Sawada M; Chiba T
    Oncogene; 2004 Jun; 23(28):4921-9. PubMed ID: 15077160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 mediates a default programme of mammary gland involution in the absence of STAT3.
    Matthews JR; Clarke AR
    Oncogene; 2005 Apr; 24(19):3083-90. PubMed ID: 15735683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A positive feedback mechanism in the transcriptional activation of Apaf-1 by p53 and the coactivator Zac-1.
    Rozenfeld-Granot G; Krishnamurthy J; Kannan K; Toren A; Amariglio N; Givol D; Rechavi G
    Oncogene; 2002 Feb; 21(10):1469-76. PubMed ID: 11896574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of STAT3 to the activation of survivin by GM-CSF in CD34+ cell lines.
    Gu L; Chiang KY; Zhu N; Findley HW; Zhou M
    Exp Hematol; 2007 Jun; 35(6):957-66. PubMed ID: 17533050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PAC1 phosphatase is a transcription target of p53 in signalling apoptosis and growth suppression.
    Yin Y; Liu YX; Jin YJ; Hall EJ; Barrett JC
    Nature; 2003 Apr; 422(6931):527-31. PubMed ID: 12673251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells.
    Gritsko T; Williams A; Turkson J; Kaneko S; Bowman T; Huang M; Nam S; Eweis I; Diaz N; Sullivan D; Yoder S; Enkemann S; Eschrich S; Lee JH; Beam CA; Cheng J; Minton S; Muro-Cacho CA; Jove R
    Clin Cancer Res; 2006 Jan; 12(1):11-9. PubMed ID: 16397018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p51/p63, a novel p53 homologue, potentiates p53 activity and is a human cancer gene therapy candidate.
    Kunisaki R; Ikawa S; Maeda T; Nakazaki Y; Kurita R; Harata M; Shutoh Y; Bai YS; Soda Y; Tanabe T; Dohi T; Kato R; Ikawa Y; Asano S; Tani K
    J Gene Med; 2006 Sep; 8(9):1121-30. PubMed ID: 16832836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The intracellular delivery of a recombinant peptide derived from the acidic domain of PIAS3 inhibits STAT3 transactivation and induces tumor cell death.
    Borghouts C; Tittmann H; Delis N; Kirchenbauer M; Brill B; Groner B
    Mol Cancer Res; 2010 Apr; 8(4):539-53. PubMed ID: 20371673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.